15 May 2021 - One of the biggest challenges payers face today is determining the value of innovative therapies in diseases with high unmet medical needs, such as cancer and rare diseases.
These novel therapies show promise, but there is often significant uncertainty regarding their added value to patients and their cost to the healthcare system. In some cases, the new therapies front-load most of the cost as is seen with gene and cell therapies.
This creates strain on healthcare system budgets, raises affordability and equity issues, and challenges decision making by health technology assessment bodies and payers.